CR20190106A - Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres - Google Patents
Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceresInfo
- Publication number
- CR20190106A CR20190106A CR20190106A CR20190106A CR20190106A CR 20190106 A CR20190106 A CR 20190106A CR 20190106 A CR20190106 A CR 20190106A CR 20190106 A CR20190106 A CR 20190106A CR 20190106 A CR20190106 A CR 20190106A
- Authority
- CR
- Costa Rica
- Prior art keywords
- autoimmune
- treatment
- inflammatory diseases
- cancers
- formula
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 230000001363 autoimmune Effects 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091005575 Bromodomain-containing proteins Proteins 0.000 abstract 2
- 102000001805 Bromodomains Human genes 0.000 abstract 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula (I) y sales de los mismos (I) en la que R1, R2, R3 y a son como se definen en el presente documento. Se ha descubierto que los compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas que contienen bromodominios a, por ejemplo, residuos de lisina acetilados y, por tanto, pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y cánceresCompounds of formula (I) and salts thereof: Formula (I) wherein R1, R2, R3 and a are as defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614934.6A GB201614934D0 (en) | 2016-09-02 | 2016-09-02 | Chemical compounds |
| PCT/EP2017/071868 WO2018041947A1 (en) | 2016-09-02 | 2017-08-31 | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190106A true CR20190106A (es) | 2019-05-02 |
Family
ID=57140084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190106A CR20190106A (es) | 2016-09-02 | 2017-08-31 | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190175571A1 (es) |
| EP (1) | EP3507283A1 (es) |
| JP (1) | JP2019526577A (es) |
| KR (1) | KR20190042701A (es) |
| CN (1) | CN109790147A (es) |
| AR (1) | AR109487A1 (es) |
| AU (1) | AU2017317724A1 (es) |
| BR (1) | BR112019004241A2 (es) |
| CA (1) | CA3035312A1 (es) |
| CL (1) | CL2019000538A1 (es) |
| CO (1) | CO2019001871A2 (es) |
| CR (1) | CR20190106A (es) |
| DO (1) | DOP2019000047A (es) |
| EA (1) | EA201990410A1 (es) |
| GB (1) | GB201614934D0 (es) |
| JO (1) | JOP20190029A1 (es) |
| MA (1) | MA46085A (es) |
| MX (1) | MX2019002491A (es) |
| PE (1) | PE20190478A1 (es) |
| PH (1) | PH12019500460A1 (es) |
| SG (1) | SG11201901673SA (es) |
| TW (1) | TW201817724A (es) |
| UY (1) | UY37393A (es) |
| WO (1) | WO2018041947A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY199759A (en) | 2016-09-02 | 2023-11-21 | Tisento Therapeutics Inc | Fused bicyclic sgc stimulators |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| CN111588721B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 |
| CN111686114B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途 |
| CN111686107B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途 |
| CN111588725B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途 |
| EP4558224A1 (en) * | 2022-07-21 | 2025-05-28 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
| CN117257964B (zh) * | 2023-10-25 | 2024-04-02 | 苏州大学 | 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3406329A1 (de) * | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| DE4034060A1 (de) * | 1990-10-26 | 1992-04-30 | Basf Ag | Biskationische azofarbstoffe |
| DE19809994B4 (de) * | 1997-03-19 | 2006-02-09 | Basf Ag | Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| JP4388997B2 (ja) * | 2006-09-05 | 2009-12-24 | 協和発酵キリン株式会社 | イミダゾール誘導体 |
| EA201001456A1 (ru) * | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
| JP5627574B2 (ja) * | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| KR20130044381A (ko) * | 2010-03-04 | 2013-05-02 | 머크 샤프 앤드 돔 코포레이션 | 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도 |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
-
2016
- 2016-09-02 GB GBGB1614934.6A patent/GB201614934D0/en not_active Ceased
-
2017
- 2017-06-16 JO JOP/2019/0029A patent/JOP20190029A1/ar unknown
- 2017-08-31 AU AU2017317724A patent/AU2017317724A1/en not_active Abandoned
- 2017-08-31 US US16/326,991 patent/US20190175571A1/en not_active Abandoned
- 2017-08-31 MX MX2019002491A patent/MX2019002491A/es unknown
- 2017-08-31 EA EA201990410A patent/EA201990410A1/ru unknown
- 2017-08-31 BR BR112019004241A patent/BR112019004241A2/pt not_active Application Discontinuation
- 2017-08-31 CN CN201780059730.0A patent/CN109790147A/zh active Pending
- 2017-08-31 CA CA3035312A patent/CA3035312A1/en not_active Abandoned
- 2017-08-31 EP EP17758878.7A patent/EP3507283A1/en not_active Withdrawn
- 2017-08-31 UY UY0001037393A patent/UY37393A/es not_active Application Discontinuation
- 2017-08-31 JP JP2019511919A patent/JP2019526577A/ja active Pending
- 2017-08-31 AR ARP170102425A patent/AR109487A1/es unknown
- 2017-08-31 MA MA046085A patent/MA46085A/fr unknown
- 2017-08-31 SG SG11201901673SA patent/SG11201901673SA/en unknown
- 2017-08-31 PE PE2019000455A patent/PE20190478A1/es unknown
- 2017-08-31 CR CR20190106A patent/CR20190106A/es unknown
- 2017-08-31 KR KR1020197009266A patent/KR20190042701A/ko not_active Ceased
- 2017-08-31 WO PCT/EP2017/071868 patent/WO2018041947A1/en not_active Ceased
- 2017-08-31 TW TW106129714A patent/TW201817724A/zh unknown
-
2019
- 2019-02-27 CO CONC2019/0001871A patent/CO2019001871A2/es unknown
- 2019-02-28 DO DO2019000047A patent/DOP2019000047A/es unknown
- 2019-02-28 CL CL2019000538A patent/CL2019000538A1/es unknown
- 2019-03-01 PH PH12019500460A patent/PH12019500460A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3507283A1 (en) | 2019-07-10 |
| BR112019004241A2 (pt) | 2019-06-04 |
| PH12019500460A1 (en) | 2019-12-16 |
| CL2019000538A1 (es) | 2019-05-17 |
| CO2019001871A2 (es) | 2019-03-08 |
| AR109487A1 (es) | 2018-12-12 |
| US20190175571A1 (en) | 2019-06-13 |
| GB201614934D0 (en) | 2016-10-19 |
| MA46085A (fr) | 2019-07-10 |
| PE20190478A1 (es) | 2019-04-04 |
| DOP2019000047A (es) | 2019-03-15 |
| KR20190042701A (ko) | 2019-04-24 |
| JOP20190029A1 (ar) | 2019-02-25 |
| CN109790147A (zh) | 2019-05-21 |
| AU2017317724A1 (en) | 2019-03-21 |
| TW201817724A (zh) | 2018-05-16 |
| EA201990410A1 (ru) | 2019-09-30 |
| JP2019526577A (ja) | 2019-09-19 |
| UY37393A (es) | 2018-03-23 |
| WO2018041947A1 (en) | 2018-03-08 |
| CA3035312A1 (en) | 2018-03-08 |
| SG11201901673SA (en) | 2019-03-28 |
| MX2019002491A (es) | 2019-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000213A (es) | Derivados de bencimidazol como inhibidores de bromodominio | |
| CR20190106A (es) | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres | |
| CY1121850T1 (el) | Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| CR20160229A (es) | Inhibidires de bromodominio | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| UY34977A (es) | 2,3-benzodiazepinas | |
| CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| MX395458B (es) | Metodos novedosos | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| SV2016005316A (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. |